EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.
| Errataetall: |
CommentIn: Ann Rheum Dis. 2022 Aug;81(8):e150. - PMID 32632031 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 7 vom: 23. Juli, Seite 851-858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Landewé, Robert Bm [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic agents |
|---|
| Anmerkungen: |
Date Completed 25.06.2020 Date Revised 25.07.2022 published: Print-Electronic CommentIn: Ann Rheum Dis. 2022 Aug;81(8):e150. - PMID 32632031 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-217877 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310833965 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310833965 | ||
| 003 | DE-627 | ||
| 005 | 20231225140942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-217877 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310833965 | ||
| 035 | |a (NLM)32503854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Landewé, Robert Bm |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.06.2020 | ||
| 500 | |a Date Revised 25.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2022 Aug;81(8):e150. - PMID 32632031 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a antirheumatic agents | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a health services research | |
| 650 | 4 | |a patient care team | |
| 650 | 4 | |a quality indicators, health care | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
| 700 | 1 | |a Kroon, Féline |e verfasserin |4 aut | |
| 700 | 1 | |a Bijlsma, Hans Wj |e verfasserin |4 aut | |
| 700 | 1 | |a Burmester, Gerd R |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona, Loreto |e verfasserin |4 aut | |
| 700 | 1 | |a Combe, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Iagnocco, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Isaacs, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a McInnes, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller-Ladner, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Openshaw, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Smolen, Josef S |e verfasserin |4 aut | |
| 700 | 1 | |a Stamm, Tanja A |e verfasserin |4 aut | |
| 700 | 1 | |a Wiek, Dieter |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze-Koops, Hendrik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 7 vom: 23. Juli, Seite 851-858 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:7 |g day:23 |g month:07 |g pages:851-858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-217877 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 7 |b 23 |c 07 |h 851-858 | ||